Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes.
Few trials of glucose-lowering drugs or strategies in people with type 2 diabetes have investigated cardiovascular outcomes, even though most patients die from cardiovascular causes despite the beneficial effects of lipid-reducing and blood pressure-lowering treatments. The evidence-based reduction...
| Hauptverfasser: | , , |
|---|---|
| Format: | Journal article |
| Sprache: | English |
| Veröffentlicht: |
Lancet
2014
|